Piper Sandler analyst David Amsellem maintained a Hold rating on Collegium Pharmaceutical (COLL – Research Report) today and set a price target ...

Piper Sandler analyst David Amsellem maintained a Buy rating on Indivior (INDV – Research Report) today and set a price target of $16.00. The ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Supernus Pharmaceuticals' FDA approval for ONAPGO in Parkinson's Disease offers optimism despite past challenges, with a ...

Q4 2024 . Management View. Amgen highlighted its robust performance in 2024, achieving 14 products annualizing over $1 billion in ...

Piper Sandler Companies (PIPR) came out with quarterly earnings of $4.80 per share, beating the Zacks Consensus Estimate of $3.62 per share. This compares to earnings of $4.03 per share a year ago.

Piper Sandler Companies reported robust financial results for Q4 2024, significantly surpassing analyst expectations. The company achieved earnings per share (EPS) of $4.80, exceeding the ...

Piper Sandler Companies reported robust fourth-quarter 2024 earnings, with earnings per share (EPS) of $4.8, surpassing the forecast of $3.93. The company's revenue reached $499 million ...

Piper Sandler Companies reported robust financial results for Q4 2024, significantly surpassing analyst expectations. The company achieved earnings per share (EPS) of $4.80, exceeding the forecasted ...

Good morning, and welcome to the Piper Sandler Companies fourth quarter and full year 2024 earnings conference call. Today's call is being recorded and will include remarks by Piper Sandler management ...